InflaRx ditches vilobelimab Phase III trial in PG

German drug developer InflaRx (Nasdaq: IFRX) saw its US-traded shares plunge 55% to $0.82 in pre-market activity today, as it announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase III trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility.

This recommendation was based on data analysis of the first 30 patients enrolled in the study, with no unexpected adverse events noted by the IDMC. InflaRx as the study sponsor remains blinded to the study results.

Prof Niels Riedemann, chief executive and founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this pioneering study targeting a significant unmet need. While the outcome is not what we had hoped it would be, InflaRx remains committed to its goal of developing new therapies for underserved patients with chronic immune-dermatological conditions, including with our oral inhibitor of C5aR, INF904, with data expected this summer.”